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Abstract
Three-dimensional (3D) printing technologies are continuously applied to novel fields, laying the foundations for a new 
industrial revolution. With regard to pharmaceutical sciences, 3D printed drug products are emerging as attractive and 
innovative tools in personalised medicine. For example, solid oral dosage forms (e.g. tablets) can be printed in a wide range 
of dosages, release profiles, geometries and sizes by simply modifying a digital model, thus providing patients with tailored 
therapies. Various 3D printing technologies have been applied to pharmaceutical manufacture in recent years, and different 
materials have been investigated to fabricate solid oral dosage forms in a broad range of properties. Therefore, the aim of this 
review is to describe the state of the art of 3D printing oral pharmaceuticals, with the view to provide formulation scientists 
with essential information to approach the development of 3D printed drug products, from digital design to final product 
quality control. Short- to long-term potential areas of application of 3D printed drug products and their relative regulatory 
pathway challenges are also presented.
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1 Introduction
Automated production of solid oral dosage forms was intro-
duced over two centuries ago [1]. The main advantages of 
such dosage forms are based on their relatively undemand-
ing and convenient manufacture, coupled with high patient 
compliance. Tablets, the most relevant exponent of the class, 
have been improved in the last decades introducing tech-
niques such as film coating, double compression and osmotic 
systems to achieve controlled and targeted release. However, 
despite the technological advances, tablet production is still 
based on tableting machines whose design has not essen-
tially changed for decades since the introduction of auto-
mated tablet presses [2]. Conventional tableting techniques 
still suffer from limitations, including challenges in direct 
compression of powders and the related need for granula-
tion. A further drawback of conventional tableting relies on 
the increasing demand for personalised treatments, likely to 
represent a significant shift in future medicine [3, 4]. Indeed, 
conventional tableting machines based on punches and dies 
are designed for a mass production market, therefore they 
are inherently lacking in flexibility; hence, a more flexible 
platform would facilitate the design, production and dispens-
ing of bespoke medicines in the near future [5].
Additive manufacturing (AM), a set of techniques includ-
ing 3D printing, has recently aroused much interest in phar-
maceutics due to its large flexibility (Fig. 1), which makes 
it a promising tool to produce the bespoke drug delivery 
devices, including solid oral dosage forms [6].
2  Designing 3D printed solid oral dosage 
forms: from digital design to bespoke 
tablet properties
2.1  Computer‑aided design tools for dosage form 
design
Prior to 3D printing solid oral dosage forms, it is essential 
to produce a digital model through computer-aided design 
(CAD) software. Digital modelling allows freedom of design 
such that the production of tablets, for instance, is no longer 
dependent on size and shape of dies and punches, eventually 
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making the same equipment suitable for producing an unlim-
ited variety of geometries. For example, our research group 
has used Tinkercad (Autodesk Inc., USA) to design a set of 
dosage forms with different shapes with the aim of assess-
ing the feasibility of SLA 3D printing for future research 
(Fig. 2).
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Fig. 1  Number of research articles related to 3D printing of solid 
oral dosage forms published within the years 1996–2010 (grouped as 
pre-2010) to 2019 (partial data updated to June 2019). Coloured bars 
represent different 3D printing technologies. Google scholar, Science 
direct and PubMed search engines were used to find relevant peer-
reviewed research articles. Key words for searching were ‘3D print-
ing’, ‘solid oral dosage forms’, ‘tablets’ and ‘personalised medicine’
Fig. 2  a, c CAD models of drug delivery devices designed on Tinkercad (Autodesk Inc, USA) and b, d 3D printed prototypes based on the same 
concept fabricated with a Form 2 SLA 3D printer (FormLabs Inc, USA) using a commercial resin
Progress in Additive Manufacturing 
1 3
2.2  Tuning dosage form properties through digital 
design
Once it is administered to the human body, a solid oral 
dosage form undertakes a sequence of steps that eventu-
ally allows the active pharmaceutical ingredients (API) to 
be absorbed through the biological membranes and pass to 
the bloodstream. Tablet disintegration and dissolution play a 
key role in such process and they are dependent upon a wide 
range of parameters.
While the type of AM technology used mainly affects 
tablet disintegration, dissolution time is influenced by the 
formulation composition and by tablet geometry.
Conventional tablet shapes include round, square, rec-
tangle, capsule and oval; however, more complex geom-
etries are limited by the nature of the compression process 
itself. In contrast, AM allows the formulation scientist to 
introduce tablet design as a novel stage in the development 
of more sophisticated products.
Tuning dosage form properties through digital design 
relies on either fabricating devices where different excipi-
ents and/or APIs are deposited in specific regions (multi-
material 3D printing), or engineering approaches (Fig. 3). 
Multi-material 3D printing of tablets includes several 
examples, like multilayer polypills and composite tablets, 
where different layers may consist of different polymers 
to control dissolution behaviour, or liquid-filled capsules 
[7–9]; a further relevant example of design-driven drug 
release mechanisms is subsequently shown in Fig. 4.
Engineering approaches are instead used to modify tab-
let properties by simply varying their geometries, with 
no need to change the formulation. For instance, chan-
nelled tablets show an accelerated drug release due to 
the increased surface area to volume ratio [10], while a 
multi-block tablet design results in a quicker fragmenta-
tion compared to no-gaps devices, thus avoiding the need 
for a disintegrant [11]. A further example is altering tablet 
density by varying the infill percentage in fused deposition 
modelling (FDM) 3D printed tablets; as a result, different 
drug release profiles can be achieved without modifying 
the formulation [12, 13]. The advantages of such approach 
are significative, since dosage forms tailored on the needs 
of single patients could be manufactured at a moment 
using the same equipment and feedstock material, with a 
positive outcome on treatments costs.
Finally, novel dosage form design could also be used to 
develop abuse deterrent formulations (ADFs); egg-shaped 
tablets were recently described as crush resistant, showing 
a force required > 500 N and, therefore, they could inhibit 
abusers’ manipulation in the form of snorting, inhaling 
and chewing [14].
Fig. 3  Schematic diagram representing examples of two different 
approaches to tune dosage forms’ properties through CAD design: a 
multi-material 3D printing and b engineering strategies (e.g. chan-
nelled tablets). Picture readapted with permission from [10, 15]
Fig. 4  Drug delivery devices designed and fabricated by Rowe et al. a breakaway tablet, b pulsatory release tablet, c immediate-extended release 
device and d enteric dual pulse release tablet. Picture adapted from [19]
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3  Applications of additive manufacturing 
in solid oral dosage form development
3.1  Powder bed‑inkjet 3D printing
In inkjet three-dimensional printing, objects are fabricated 
by spreading a thin layer of a powdered material which is 
then bound in selected regions by printing a binder solu-
tion using an inkjet-type nozzle. Once bound, the powder 
bed is lowered by a piston and the process is repeated 
until the whole part is produced. From a pharmaceutical 
perspective, such a process implies the formulation of both 
a powder mixture and a liquid ink, where the latter rep-
resents the most challenging step due to potential nozzle 
clogging issues [16]. The API can be either solubilised 
in the liquid binder or blended with the powder mixture. 
When the drug is dissolved in the liquid binder, it can 
be loaded at very low concentrations in the tablets; this 
would benefit the formulation of drug products requiring 
ultralow dosages (e.g. hormones). When the API is instead 
dispersed in the powder blend, the quantity of necessary 
excipients reduces because of the fewer formulation issues 
to overcome.
Three-dimensional printing potential in drug delivery 
was first explored in 1996 at the MIT, where a desktop 3D 
printer (developed at the MIT itself) was used to produce a 
device made of polymeric material featuring internal cells 
[17]. The ability of controlling drug release profiles was 
demonstrated by depositing dyes only in selected cells, 
thus introducing a new feature in solid dosage form design 
and development: microstructural control.
Following this proof of concept, 3D printed dosage 
forms with both erosion and diffusion drug release mech-
anism were realised by using specific tablets’ design and 
conventional pharmaceutical excipients [18].
The introduction of more sophisticated technologies, 
such as the TheriForm™ process, also made it possible 
to tune tablet properties through spatial control of com-
position. Immediate-extended release, breakaway, enteric 
dual pulsatory and dual pulsatory tablets are examples of 
dosage forms produced following digital design modelling 
(Fig. 4), highlighting a flexibility which is unachievable 
with conventional tablet pressing techniques [19].
Another appealing application of powder-bed 3D printing 
is designing zero-order drug release devices [20]. Zero-order 
release kinetics, defined as constant drug release over time, 
is a desirable attribute for oral formulations containing APIs 
with short half-life or narrow therapeutic index, because this 
allows for minimum fluctuations in drug plasma levels [21, 
22]. Reported examples of constant release 3D printed tab-
lets include devices made of a top and bottom layer imper-
meable to water to limit drug release from the sides of the 
tablets, and a middle compartment formed by annular sec-
tions with a porosity gradient achieved by printing a lower 
amount of binder solution (Fig. 5) [20]. The porosity gra-
dient was exploited to have a stable erosion volume, thus 
resulting in a linear drug release.
Another strategy to achieve linear drug release can be 
based on torus-shaped tablets, designed to release drug mol-
ecules only from the outer and inner surfaces [23].
Powder-bed 3D printing can be furthermore employed 
to formulate fast-disintegrating tablets, achieved by binding 
powdered material in a gradient fashion, resulting in a final 
tablet with inner compartments of loose powder and a highly 
porous structure (Fig. 6) [24].
High porosity also characterises Spritam®, the first medi-
cine fabricated through a 3D printing process—known as 
ZipDose®—to gain Food and Drug Administration approval 
in 2015, marketed by Aprecia Pharmaceuticals [25]. Spri-
tam® is an antiseizure drug containing the active ingredient 
levetiracetam and the rationale behind its development is 
that the highly porous structure allows the tablet to disinte-
grate in a mean of 11 s, allowing a fast onset of action [26, 
27].
Although powder-bed 3D printing allowed important 
proof of concept studies in 3D printing pharmaceuticals, 
demonstrating flexibility of the technique as well as the 
feasibility of using conventional excipients, its application 
remains poor. Limitations mainly attributable to the use of 
powders, such as low powder flowability, influence both the 
process and the final product (Prescott and Barnum, 2000). 
A low powder flowability can cause the deposition of non-
uniform layers, thus affecting dosing homogeneity [16]. 
Furthermore, the use of powders affects the resolution of 
Fig. 5  Schematic representation of a material gradients tablet. A different porosity degree allows a faster erosion when the surface area decreases 
resulting in a constant drug release Picture adapted from [20]
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printed tablets, usually resulting in a rough surface finishing, 
which might require coating processes to gain a satisfactory 
patient acceptability. Lastly, despite the valid applications 
previously reported, highly porous structures showed high 
friability that could not meet the pharmacopoeia require-
ments [16, 24, 28].
3.2  Pressure‑assisted microsyringe 3D printing
Pressure-assisted microsyringe 3D printing (PAM) was 
introduced in 2006 and represented a breakthrough point 
in the accessibility of affordable multi-material 3D printers 
[29]. PAM 3D printers are equipped with one or multiple 
syringes that can deposit a variety of materials, including 
liquids, gels or paste.
As different materials can be printed at the same time, the 
first attempt to manufacture oral dosage forms using such 
technology describes the formulation of bilayer tablets using 
gels consisting of suitable excipients to obtain immediate 
and sustained release layers [30].
More complex PAM 3D printers also allows the produc-
tion of ‘polypills’ containing more than one active ingredient 
with different release profiles [31, 32]. The polypill concept 
could arouse much interest in the development of person-
alised therapies in geriatric patients, as polypharmacy is a 
well-known issue in this patient group [33]. An example of 
a reported 3D printed polypill consists of three compart-
ments designed as a captopril-loaded osmotic pump on the 
bottom and two separate top sections containing nifedipine 
and glipizide (Fig. 7) as part of an antihypertensive regime 
for diabetic patients [32].
A five API polypill was also developed, including three 
sustained release compartments containing pravastatin, ate-
nolol and ramipril, and a top immediate release layer loaded 
Fig. 6  Schematic representation of a fast disintegrating tablet. Partially printed regions consist in loose powder that allows faster disintegration 
and dissolution. Picture adapted from [24]
Fig. 7  Concept of a 3D printed 
polypill consisting of an 
osmotic pump coupled with a 
sustained release section and 
containing three different APIs. 
Picture reproduced with permis-
sion from [32]
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with aspirin and hydrochlorothiazide [31]. Compartments 
containing different APIs were separated using cellulose 
acetate to form a hydrophobic barrier. An important consid-
eration when developing polypills regards the allocation of 
the APIs in the different layers; the top and the bottom layers 
will expose a larger area to the media and, therefore, drugs 
in those layers will be released faster. An effective strategy 
can be to include the less soluble APIs in the external layer, 
and the more soluble in the inner ones [34].
Despite their attractive features, PAM 3D printed tablets 
share a limitation related to the drying step required after 
production. In fact, the use of solvents such as ethanol, ace-
tone and dimethyl sulfoxide is essential to produce pastes for 
PAM printing. Besides any toxicity concerns, which require 
the final product to be compliant with the ICH Guideline 
Q3C (R6) [35], an effective drying step is usually required 
when solvents are used, resulting in the possible degrada-
tion of thermolabile APIs when heat is used. Drying is also 
a time-consuming process (24 h needed to dry a single tab-
let printed in 25 min) [32]. Even when water was used to 
replace organic solvents, reducing drying time to 3 h at 80 
°C [36], it should be considered that residual humidity in the 
final product could cause hydrolytic degradation of active 
ingredients and promote microbial growth [37].
3.3  Fused deposition modelling
Fused deposition modelling (FDM) is currently the most 
employed 3D printing technique in solid oral dosage form 
development; such a trend is due to the availability of inex-
pensive equipment that can even be coupled to conventional 
pharmaceutical processes such as hot melt extrusion (HME) 
and film coating [38]. Introduced in 1988 [39], FDM 3D 
printing became affordable to the general public in 2005 due 
to the RepRap (replicating rapid prototyper) project [40]. In 
FDM 3D printers, the feedstock material is a thermoplastic 
filament, which is melted and extruded through a heated 
nozzle; once extruded, the material returns to a solid, giving 
the object the desired geometry.
A characteristic parameter in FDM 3D printing is the 
infill percentage, defined as the printing density of a certain 
patterned structure inside the object (Fig. 8). Tuning the 
infill percentage has been explored to assess its impact on 
drug release and mechanical properties of tablets [41–43].
Early attempts of using FDM 3D printing to manufac-
ture solid oral dosage forms reported polyvinyl alcohol 
(PVA) filaments loaded with model drugs by passive dif-
fusion [44–46]. PVA is a water-soluble polymer having the 
advantage of being classified among Generally Recognised 
As Safe (GRAS) excipients [47] as well as a commercially 
available material for FDM 3D printing [48]; also, a novel 
PVA specifically designed for HME known as Parteck® 
MXP is available [49]. However, drug loading of PVA fila-
ments by passive diffusion is low, therefore limiting the 
application to low dosages of active ingredients [44, 46].
Strategies to overcome such limitation are based on the 
application of hot melt extrusion (HME), a standard manu-
facturing process in the pharmaceutical industry, to produce 
printable filaments from pharmaceutical-grade excipients. 
Coupling HME with FDM 3D printing to improve drug 
loading of commercially available filaments such as PVA, 
does not affect the extrusion performances and, therefore, 
allows printing of devices with attractive design [15].
However, while PVA was initially used in proof of con-
cept studies due to its established application in FDM, other 
pharmaceutical-grade polymers have been recently investi-
gated to produce printable filaments via HME (Fig. 9) [50, 
51]. For example, hydroxypropyl methylcellulose (HPMC) 
and Soluplus®-based filaments were used to fabricate zero-
order drug release tablets [52], while Eudragit E PO was 
used to formulate filaments for immediate release tablets 
[53]. However, Sadia et al. (2016) reported a significant 
decrease in drug content after printing at a temperature of 
135 °C, highlighting the main limitation of FDM 3D print-
ing of medicines [53].
Temperatures up to 200 °C can be required in FDM, mak-
ing this operation clearly unsuitable for thermolabile APIs 
[45, 49]. To overcome this limitation, filaments extrudable at 
temperatures lower than 100 °C are required. However, FDM 
Fig. 8  Cross-sectional views of FDM 3D printed tablets with different infill percentage. Picture reproduced with permission from [44]
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is inherently designed to work with thermoplastic materials 
extruded at temperatures over 100 °C.
Furthermore, the production of custom-made filaments 
introduces a more complex step to the relatively easy 3D 
printing process, requiring several optimisation studies to 
assess properties such as stiffness, toughness, melt viscosity 
and moisture uptake, usually altered by high drug loading 
[52, 54]; filaments with unsuited mechanical properties can 
cause nozzle blockage and, therefore, printing failures [55].
3.4  Selective laser sintering
Selective laser sintering (SLS) works on similar principles 
as powder-bed inkjet 3D printing, with the difference that 
powder particles are sintered by a high-energy laser rather 
than bound by liquid solutions. The laser writes a specific 
pattern on the surface of the powder bed, corresponding to 
each layer. The immediate advantage of this is that organic 
solvents are not required, excluding the toxicity concerns 
and further drying steps.
The first application of SLS for pharmaceutical devel-
opment consisted in the fabrication of polycaprolactone-
based drug delivery devices [56]. Manufacturing of tab-
lets by SLS using pharmaceutical polymers was recently 
described [57]; the presence of an additive absorbing light 
at the same wavelength as the laser (445 nm) was essential 
to observe particles sintering and Candurin® gold sheen 
was added to the polymer blend. Modulating laser scan-
ning speed was also found as a useful strategy to alter 
tablets’ porosity.
Such an approach was subsequently exploited to produce 
orally disintegrating tablets (ODTs) able to disintegrate 
within 4 s (Fig. 10), and dosage forms with a gyroid lattice 
geometry [58, 59]. The latter demonstrated the ability to 
tailor drug release by simply adjusting the tablet’s design, 
thus avoiding modification in the formulation.
Fig. 9  Diagram describing 
pharmaceutical grade poly-
mers commonly employed in 
HME-FDM 3D printing. PVA is 
currently the most used polymer 
in solid oral dosage forms 
production
Eudragit E PO
Ethyl cellulose
Hydroxypropyl cellulose
Hydroxypropyl methylcellulose
Hydroxypropyl methylcellulose acetate succinate
Kollidon IR
Kollidon VA 64
Polyethylene glycol
Polyvinyl alcohol
Others
Fig. 10  Hydroxypropyl methylcellulose and Kollidon VA64 based tablets produced via SLS 3D printing. Picture reproduced with permission 
from [58]
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However, it should be considered that in all the studies 
carried out on SLS 3D printed dosage forms, paracetamol 
is the only drug used; therefore, there is no evidence that 
thermolabile APIs can be employed with this technique. In 
fact, when the laser hits a specific point of the powder bed, 
it increases the temperature. The local rise in temperature 
reaches a value between the melting point of the powdered 
material (Tm) and Tm/2, otherwise sintering would not occur. 
Despite no evidence of degradation of thermostable drug 
being observed [57], high heating developed during opera-
tion as well as the effect of high-power lasers may affect 
thermolabile APIs and further investigation is required. 
Also, sintering powdered materials makes tablets’ appear-
ance quite rough and that should be considered from a 
patient acceptability perspective.
3.5  Stereolithography
Stereolithography (SLA) is so far the least studied tech-
nique in solid oral dosage form development (Fig. 1); this 
is mainly attributable to the different working principles of 
SLA requiring specific materials currently not GRAS listed. 
In SLA, the fabrication of solid objects is based on a pho-
topolymerisation process occurring when a focused laser 
beam hits a liquid photosensitive resin contained in a vat; 
a mirror galvanometer system directs the laser beam onto 
the liquid resin, drawing a pattern corresponding to each 
single layer.
Photopolymerisable resins employed in SLA are gen-
erally mixtures of reactive monomers and oligomers that 
cross-link when exposed to light of a certain wavelength 
in the presence of a photoinitiator. Important factors that 
can be controlled in SLA are laser power (mW) and laser 
speed (mm/s); they can be used to tune the properties of the 
printed object or optimised to avoid potential degradation 
of photolabile APIs.
SLA is a very intriguing technique, as it does not share 
some of the limitations of the other 3D printing techniques. 
Since powders are not used to directly feed the machine, 
flow properties do not represent a concern; SLA printed 
structures do not present porous structures, therefore physi-
cal properties are advantageous; heating is not required dur-
ing operation and degradation of APIs might be related only 
to the effect of the UV laser in the case of photolabile drugs 
being used. Furthermore, SLA offers the highest printing 
resolution among other technologies, an important feature 
to consider when developing complex geometries. In fact, 
as the resolution along the X–Y axis is dictated by the width 
of the laser beam, resolution up to 70 µm can be achieved 
in recent commercial printers [60]; resolution on the Z axis 
(vertical resolution) is instead controlled by the depth of 
curing that can be adjusted by varying laser settings and 
composition of the resin [48].
On the other hand, resins used in SLA are highly reactive 
and the presence of unreacted compounds, coupled with the 
nature itself of the free radical polymerisation process, is a 
concern holding back the development of this technique in 
the pharmaceutical field.
The first application of SLA in the formulation of 3D 
printed tablets was described by Wang et al. (2016), who 
produced dosage forms in a torus geometry using a photo-
sensitive resin consisting of polyethylene glycol diacrylate 
700 (PEGDA 700) and diphenyl(2,4,6-trimethylbenzoyl) 
phosphineoxide (TPO) as a photoinitiator (Fig. 11) [61]. 
Polyethylene glycol 300 was found to increase drug release 
and it is likely that it reduces the degree of cross-linking of 
PEGDA. 4-aminosalicylic acid (4-ASA) and paracetamol 
were used as model drugs and degradation was not observed.
SLA was also investigated to fabricate drug-loaded hydro-
gels, and a photoinitiator system based on riboflavin and 
triethanolamine was tested as a biocompatible alternative to 
TPO [62]. The feasibility of SLA in printing complex shapes 
encourages the study of the effect of dosage form geometries 
on drug release profiles. In fact, drug release profiles could 
be affected with unpredictable effects by modifying size and/
or shape of tablets, and preliminary evidence shows that the 
surface area/volume ratio (SA/V) is the parameter with the 
highest influence on release profiles [63].
Although the reported works describe the validity of SLA 
to produce solid oral dosage forms, there remain significant 
limitations to be addressed, in particular the toxicity of pho-
topolymer resins coupled with the low availability of safe 
photopolymerisable compounds and novel excipients. To the 
best of our knowledge, no data are currently available on the 
cytotoxicity tablets produced using SLA, and studies in the 
Fig. 11  Torus-shaped tablets printed via SLA. Tablets were formu-
lated using PEGDA 700 and PEG300 at different ratio; a paracetamol 
and b 4-ASA were loaded in the liquid resin and then printed. Picture 
reproduced with permission from [61]
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field are therefore required to confirm the good potential of 
the technique. Further, screening and evaluation of mono-
mers, oligomers and photoinitiators could enlarge the pool of 
materials suitable for SLA tablet manufacture, with specific 
enthusiasm on the development of novel excipients.
4  Areas of application of 3D printed drug 
products
4.1  Personalised pharmacological treatments
The rationale behind 3D printing pharmaceuticals relies on 
providing an adaptable platform to produce and dispense 
tailored drug products [4]. 3D printing can serve the purpose 
by manufacturing dosage forms with adjustable properties, 
e.g. bespoke drug dosages and/or release profiles [54, 64]. 
Personalising medicinal products also encompasses features 
such as size, shape, texture, colour and flavour of oral dos-
age forms, all of which may influence patients’ acceptability 
criteria [65–67]. Providing treatments able to satisfy indi-
vidual needs is considered a goal of medicine in the near 
future; continuous progresses in pharmacogenomics and 
bioinformatics will help to predict patients’ responses to 
medicinal products, improving therapeutic outcomes with 
benefits to both patients and the economy [3]. From a clini-
cal perspective, personalisation of pharmacotherapies shows 
higher importance where drugs with a narrow therapeutic 
index (NTI) are used. An important application could be 
represented by oral anticoagulants [68–70]; coumarin-based 
regimens are known to be poorly managed because of the 
many interactions with food and other drugs, requiring the 
continuous INR profile monitoring and dose titration [71]; 
frequent or even daily dose adjustments could be easily 
made by modifying the digital design used to 3D print a 
dosage form, with no need to alter the formulation.
Personalising medicine also means providing an alterna-
tive drug product to those patients with known allergies to 
commonly used excipients, such as lactose [72]. A commer-
cial alternative is not always available, and some individuals 
may suffer serious side effects when exposed to the allergen.
Moreover, personalising medicine could address polyp-
harmacy issues, especially for elderly patients [33]. More 
active ingredients can be combined in the bespoke ‘polyp-
ills’, reducing the daily amount of tablet intake, improving 
patient compliance and therapy adherence. For instance, 
specific formulations could be designed for the treatment 
of those diseases requiring a complex therapeutic regimen, 
such as diabetes [7, 31, 32].
Hospital pharmacies have a primary role in dispensing 
such personalised pharmaceutical products. The future for 3D 
printing in this setting could see a complete cycle of diagno-
sis through to treatment all at the point of care. A possible 
example would see a patient in hospital undertaking a test 
which elucidates the individuals’ personal profile, this may be 
based on genetics or molecular composition of fluid samples. 
Based on this, the patient would receive a bespoke prescrip-
tion which precisely addresses the patients’ needs. This precise 
and personalised prescription would then be translated into a 
bespoke dosage form via an adaptable and dynamic dosage 
form design and a suitable 3D printer. With current technol-
ogy, the time to produce quality 3D printed tablets is short, 
typically 1–2 h at most and further technological advances 
within the printers and materials for tablet production promises 
to reduce this further. When coupled with parallel advances in 
testing, diagnosis and data processing informing personalised 
medicine, this approach promises to deliver truly personalised 
medicine.
4.2  On‑demand production of drug products
Due to the highly expensive equipment and the spacious facili-
ties required, setting up a conventional pharmaceutical produc-
tion site is limited to industrial plants, where large batches are 
daily manufactured and transported remotely.
Despite its established effectiveness, such a system is not 
without limitations: for example, failure to supply medicines to 
remote areas of the world and in developing countries, due to 
difficulties that can be encountered in long-distance transport, 
natural disasters or conflicts [73].
Such limitations can potentially be overcome with the 
establishment of novel technologies like 3D printing, which 
is emerging as a promising tool for the on-demand produc-
tion of oral dosage forms [74]. Low cost, compact size and 
almost unlimited production flexibility make 3D printing a 
frontrunner technology capable of being employed in various 
scenarios where the same machine can be used to fabricate 
personalised medicines, prosthesis, equipment and even to 
synthesise APIs [75–77]. Such potential could be exploited 
to accelerate clinical trials, where it is necessary to design a 
wide range of dosage forms with different dosages and release 
profiles to evaluate novel API efficacy [4]. This application is 
likely the most suitable to meet the pharmaceutical industry 
needs through 3D printing.
Further, an ambitious application of pharmaceutical AM 
relies on future space exploration, since AM has already been 
experimented on the International Space Station to produce 
tools on-site [78]. It is, therefore, reasonable to imagine that 
long space journeys involving human crews will require ver-
satile pharmaceutical workstations able to supply medicines 
and medical devices with unique characteristics.
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5  The regulatory framework
At the present time, no regulatory pathway for bespoke 3D 
printed oral dosage forms is established. Although Aprecia 
Pharmaceuticals demonstrated how 3D printing can be a 
realistic method of manufacture, representing a breakthrough 
point for the development of the technology, Spritam® is not 
considered as a personalised product, as it is only available 
in four dosages. Therefore, even though 3D printing can 
meet the requirements for pharmaceuticals manufacture, it 
seems that approval can only be granted when the process 
is intended for mass production. However, current research 
on 3D printing in pharmaceutics is mainly focused on per-
sonalised medicine, targeting the fabrication of dosage forms 
with properties varying from batch to batch. This is inher-
ently in conflict with the requirements of pharmaceutical 
production processes, for which the inter-batch variability 
must be guaranteed to a minimum. Given such limitations 
caused by legislation, it will likely take time for 3D printing 
approaches to be awarded widespread regulatory approval, 
as changes in regulation will likely be implemented incre-
mentally. For the present, it is likely that the manufacture of 
3D printed medicines will be limited to fixed dose units as 
has proven successful in the case of Spritam® [79].
Considering the key steps in 3D printing, weak points in 
validating the process rely on the lack of 3D printers specifi-
cally designed for pharmaceutical applications, on the mate-
rial selection—in case novel excipients are needed—and on 
the unavailability of advanced CAD software, able to adapt 
tablet design to the desired therapeutical properties (Fig. 12).
A further observation regarding the on-demand manufac-
turing of a wide range of medicines, for example in hospital 
pharmacies, highlights the need of appropriate and accurate 
analytical procedures to ensure final product quality; process 
analytical technologies such as near infrared spectroscopy 
and Raman confocal microscopy were recently found as 
valid techniques for the intended purpose [80].
Although it is necessary for the scientific community 
to build a solid knowledge background to understand and 
improve the whole manufacturing process from dosage 
form design to the relative quality control, it is essential 
that regulatory agencies issue guidelines that can promote 
development and safe application of 3D printing technology 
in clinical scenarios.
6  Conclusion
Several formulation approaches to three-dimensional print-
ing of solid oral dosage forms have been described and dis-
cussed. Selecting which 3D printing technique is employed 
to fabricate drug products requires careful consideration of 
the respective advantages and disadvantages of each tech-
nique, as well as the final product’s desired characteris-
tics. For example, fused deposition modelling is emerging 
as a frontrunner technology due to its compatibility with 
established pharmaceutical excipients and processes, but it 
should not be considered in the development of thermolabile 
API-based products. Another example is stereolithography, 
still in its infancy due to its toxicity concerns; however, its 
high-resolution power could be exploited to study the rela-
tionship between complex design and dosage form proper-
ties. According to this, an important step toward the clinical 
application of 3D printing is to identify the advantages of 
the different technologies with respect to the production of 
medicinal products and merge them in a 3D printer specifi-
cally designed for pharmaceutical manufacture.
To conclude, we believe that the path to the medical 
application of 3D printing has now been traced and it is, 
therefore, possible to envision a future with smart, acces-
sible and personalised medicine, where novel technologies 
will not replace conventional large-scale manufacturing, but 
rather meet the unmet needs of contemporary medicine.
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